Symbols / APRE Stock $0.90 -3.26% Aprea Therapeutics, Inc.
APRE (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
Ratings
Current target
$0.90
Low
$1.20
High
$7.00
Mean
$4.40
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-05-07 | init | Oppenheimer | — → Outperform | $5 |
| 2026-03-31 | reit | Wedbush | Outperform → Outperform | $7 |
| 2026-03-31 | main | HC Wainwright & Co. | Buy → Buy | $1 |
| 2026-02-10 | main | Wedbush | Outperform → Outperform | $7 |
| 2026-01-29 | main | HC Wainwright & Co. | Buy → Buy | $4 |
| 2025-12-18 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-01-15 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-12-17 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-11-18 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-10-24 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-08-13 | reit | Wedbush | Outperform → Outperform | $11 |
| 2024-08-12 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-06-24 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-06-17 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-05-14 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-03-27 | main | Wedbush | Outperform → Outperform | $11 |
| 2024-03-26 | main | HC Wainwright & Co. | Buy → Buy | $20 |
| 2023-11-01 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2023-09-13 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2023-08-10 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
- Early human data on Aprea cancer drug lands ASCO 2026 poster slot - Stock Titan ue, 21 Apr 2026 07
- $APRE stock is up 24% today. Here's what we see in our data. | APRE Stock News - Quiver Quantitative Fri, 10 Apr 2026 07
- This Aprea Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday - Sahm hu, 07 May 2026 07
- Oppenheimer initiates Aprea stock with Outperform on WEE1 inhibitor potential - Investing.com hu, 07 May 2026 10
- Should I buy Aprea Therapeutics (APRE) - Zacks Investment Research Wed, 14 Jan 2026 08
- Oppenheimer initiates coverage of Aprea Therapeutics (APRE) with outperform recommendation - MSN hu, 07 May 2026 07
- Cancer drug developer raises $30M to fund lead trial into 2028 - Stock Titan Mon, 30 Mar 2026 07
- Oppenheimer initiates Aprea stock with Outperform on WEE1 inhibitor potential - Investing.com Nigeria hu, 07 May 2026 11
- $APRE stock is down 25% today. Here's what we see in our data. - Quiver Quantitative hu, 29 Jan 2026 08
- CatalYm picks ex-Aprea CEO Christian Schade to chair board - Stock Titan ue, 28 Apr 2026 07
- [EFFECT] Aprea Therapeutics, Inc. SEC Filing - Stock Titan Wed, 29 Apr 2026 07
- APRE | Aprea Therapeutics, Inc. Common Executive Compensation - Quiver Quantitative Sun, 03 May 2026 14
- Aprea Therapeutics (NASDAQ: APRE) reporting group discloses 9.9% stake - Stock Titan Mon, 27 Apr 2026 07
- 74.35M shares registered for resale by Aprea Therapeutics (NASDAQ: APRE) - Stock Titan Wed, 29 Apr 2026 07
- Reverse split and director votes in Aprea Therapeutics (NASDAQ: APRE) 2026 proxy - Stock Titan hu, 30 Apr 2026 07
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
13.23
-7.58%
|
14.32
-7.45%
|
15.47
-58.60%
|
37.37
|
| Research And Development |
|
7.04
-24.78%
|
9.36
+22.76%
|
7.63
-53.50%
|
16.40
|
| Selling General And Administration |
|
6.48
+0.28%
|
6.46
-23.36%
|
8.43
-59.81%
|
20.97
|
| General And Administrative Expense |
|
6.48
+0.28%
|
6.46
-23.36%
|
8.43
-59.81%
|
20.97
|
| Other Gand A |
|
6.48
+0.28%
|
6.46
-23.36%
|
8.43
-59.81%
|
20.97
|
| Other Operating Expenses |
|
-0.29
+80.98%
|
-1.50
-157.63%
|
-0.58
|
—
|
| Total Expenses |
|
13.23
-7.58%
|
14.32
-7.45%
|
15.47
-58.60%
|
37.37
|
| Operating Income |
|
-13.23
+7.58%
|
-14.32
+7.45%
|
-15.47
+58.60%
|
-37.37
|
| Total Operating Income As Reported |
|
-13.23
+7.58%
|
-14.32
+7.45%
|
-15.47
+86.36%
|
-113.39
|
| EBITDA |
|
-13.21
+7.59%
|
-14.30
+7.55%
|
-15.46
+58.41%
|
-37.19
|
| Normalized EBITDA |
|
-13.12
+8.72%
|
-14.37
+6.85%
|
-15.43
-140.01%
|
38.55
|
| Reconciled Depreciation |
|
0.02
-2.70%
|
0.02
+216.48%
|
0.01
-96.22%
|
0.19
|
| EBIT |
|
-13.23
+7.58%
|
-14.32
+7.45%
|
-15.47
+58.60%
|
-37.37
|
| Total Unusual Items |
|
-0.10
-232.76%
|
0.07
+284.45%
|
-0.04
+99.95%
|
-75.74
|
| Total Unusual Items Excluding Goodwill |
|
-0.10
-232.76%
|
0.07
+284.45%
|
-0.04
+99.95%
|
-75.74
|
| Special Income Charges |
|
—
|
—
|
0.00
+100.00%
|
-76.02
|
| Other Special Charges |
|
—
|
—
|
—
|
76.02
|
| Net Income |
|
-12.60
+2.77%
|
-12.96
+9.30%
|
-14.29
+87.32%
|
-112.66
|
| Pretax Income |
|
-12.60
+2.77%
|
-12.96
+9.30%
|
-14.29
+87.32%
|
-112.66
|
| Net Non Operating Interest Income Expense |
|
0.65
-49.42%
|
1.29
+5.31%
|
1.22
+172.84%
|
0.45
|
| Net Interest Income |
|
0.65
-49.42%
|
1.29
+5.31%
|
1.22
+172.84%
|
0.45
|
| Interest Income Non Operating |
|
0.65
-49.42%
|
1.29
+5.31%
|
1.22
+172.84%
|
0.45
|
| Interest Income |
|
0.65
-49.42%
|
1.29
+5.31%
|
1.22
+172.84%
|
0.45
|
| Other Income Expense |
|
-0.02
-124.82%
|
0.07
+284.45%
|
-0.04
+99.95%
|
-75.74
|
| Other Non Operating Income Expenses |
|
0.08
|
—
|
—
|
—
|
| Gain On Sale Of Security |
|
-0.10
-232.76%
|
0.07
+284.45%
|
-0.04
-113.83%
|
0.28
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-12.60
+2.77%
|
-12.96
+9.30%
|
-14.29
+87.32%
|
-112.66
|
| Net Income From Continuing Operation Net Minority Interest |
|
-12.60
+2.77%
|
-12.96
+9.30%
|
-14.29
+87.32%
|
-112.66
|
| Net Income From Continuing And Discontinued Operation |
|
-12.60
+2.77%
|
-12.96
+9.30%
|
-14.29
+87.32%
|
-112.66
|
| Net Income Continuous Operations |
|
-12.60
+2.77%
|
-12.96
+9.30%
|
-14.29
+87.32%
|
-112.66
|
| Normalized Income |
|
-12.50
+4.04%
|
-13.03
+8.54%
|
-14.25
+61.41%
|
-36.92
|
| Net Income Common Stockholders |
|
-12.60
+2.77%
|
-12.96
+9.30%
|
-14.29
+87.32%
|
-112.66
|
| Diluted EPS |
|
—
|
-2.35
+40.51%
|
-3.95
+94.19%
|
-67.99
|
| Basic EPS |
|
—
|
-2.35
+40.51%
|
-3.95
+94.19%
|
-67.99
|
| Basic Average Shares |
|
—
|
5.51
+52.31%
|
3.62
+118.32%
|
1.66
|
| Diluted Average Shares |
|
—
|
5.51
+52.31%
|
3.62
+118.32%
|
1.66
|
| Diluted NI Availto Com Stockholders |
|
-12.60
+2.77%
|
-12.96
+9.30%
|
-14.29
+87.32%
|
-112.66
|
| Total Other Finance Cost |
|
—
|
—
|
—
|
-0.45
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
15.93
-33.55%
|
23.98
+5.87%
|
22.65
-24.89%
|
30.16
|
| Current Assets |
|
15.56
-34.00%
|
23.58
+4.68%
|
22.52
-25.31%
|
30.15
|
| Cash Cash Equivalents And Short Term Investments |
|
14.60
-36.11%
|
22.85
+5.75%
|
21.61
-24.94%
|
28.79
|
| Cash And Cash Equivalents |
|
14.60
-36.11%
|
22.85
+5.75%
|
21.61
-24.94%
|
28.79
|
| Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Other Current Assets |
|
0.96
+32.45%
|
0.73
-20.57%
|
0.91
-33.11%
|
1.37
|
| Total Non Current Assets |
|
0.37
-7.73%
|
0.40
+212.49%
|
0.13
+5461.35%
|
0.00
|
| Net PPE |
|
0.06
-26.64%
|
0.08
-7.74%
|
0.09
+3707.07%
|
0.00
|
| Gross PPE |
|
0.15
+0.00%
|
0.15
+11.18%
|
0.14
+205.09%
|
0.05
|
| Accumulated Depreciation |
|
-0.09
-29.98%
|
-0.07
-44.53%
|
-0.05
-16.37%
|
-0.04
|
| Machinery Furniture Equipment |
|
0.01
+0.00%
|
0.01
+0.00%
|
0.01
+0.00%
|
0.01
|
| Other Properties |
|
0.15
+0.00%
|
0.15
+11.62%
|
0.13
+231.96%
|
0.04
|
| Other Non Current Assets |
|
0.31
-2.95%
|
0.32
+690.41%
|
0.04
|
—
|
| Total Liabilities Net Minority Interest |
|
3.49
-25.26%
|
4.67
-17.99%
|
5.70
+26.25%
|
4.51
|
| Current Liabilities |
|
2.76
-17.75%
|
3.36
-23.36%
|
4.39
+37.00%
|
3.20
|
| Payables And Accrued Expenses |
|
1.99
-31.15%
|
2.90
+1.98%
|
2.84
+57.49%
|
1.80
|
| Payables |
|
0.71
-47.22%
|
1.35
-19.05%
|
1.67
+98.20%
|
0.84
|
| Accounts Payable |
|
0.71
-47.22%
|
1.35
-19.05%
|
1.67
+98.20%
|
0.84
|
| Current Accrued Expenses |
|
1.28
-17.08%
|
1.54
+32.02%
|
1.17
+21.76%
|
0.96
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.77
+65.71%
|
0.47
-54.27%
|
1.02
-27.25%
|
1.40
|
| Current Debt And Capital Lease Obligation |
|
—
|
—
|
—
|
—
|
| Current Capital Lease Obligation |
|
—
|
—
|
—
|
0.00
|
| Current Deferred Liabilities |
|
—
|
0.00
-100.00%
|
0.53
|
0.00
|
| Current Deferred Revenue |
|
—
|
0.00
-100.00%
|
0.53
|
0.00
|
| Total Non Current Liabilities Net Minority Interest |
|
0.73
-44.52%
|
1.31
+0.00%
|
1.31
+0.00%
|
1.31
|
| Long Term Debt And Capital Lease Obligation |
|
—
|
—
|
—
|
0.00
|
| Long Term Capital Lease Obligation |
|
—
|
—
|
—
|
0.00
|
| Preferred Securities Outside Stock Equity |
|
0.73
-44.52%
|
1.31
+0.00%
|
1.31
+0.00%
|
1.31
|
| Stockholders Equity |
|
12.44
-35.56%
|
19.31
+13.88%
|
16.95
-33.89%
|
25.64
|
| Common Stock Equity |
|
12.44
-35.56%
|
19.31
+13.88%
|
16.95
-33.89%
|
25.64
|
| Capital Stock |
|
0.01
+49.46%
|
0.01
+46.71%
|
0.00
+40.72%
|
0.00
|
| Common Stock |
|
0.01
+49.46%
|
0.01
+46.71%
|
0.00
+40.72%
|
0.00
|
| Share Issued |
|
8.19
+49.47%
|
5.48
+46.68%
|
3.74
+40.73%
|
2.66
|
| Ordinary Shares Number |
|
8.19
+49.47%
|
5.48
+46.68%
|
3.74
+40.73%
|
2.66
|
| Additional Paid In Capital |
|
356.71
+1.64%
|
350.97
+4.57%
|
335.64
+1.69%
|
330.06
|
| Retained Earnings |
|
-333.64
-3.92%
|
-321.04
-4.21%
|
-308.08
-4.86%
|
-293.80
|
| Gains Losses Not Affecting Retained Earnings |
|
-10.63
-0.07%
|
-10.63
-0.15%
|
-10.61
+0.11%
|
-10.62
|
| Other Equity Adjustments |
|
-10.63
-0.07%
|
-10.63
-0.15%
|
-10.61
+0.11%
|
-10.62
|
| Total Equity Gross Minority Interest |
|
12.44
-35.56%
|
19.31
+13.88%
|
16.95
-33.89%
|
25.64
|
| Total Capitalization |
|
12.44
-35.56%
|
19.31
+13.88%
|
16.95
-33.89%
|
25.64
|
| Working Capital |
|
12.80
-36.70%
|
20.22
+11.47%
|
18.14
-32.71%
|
26.95
|
| Invested Capital |
|
12.44
-35.56%
|
19.31
+13.88%
|
16.95
-33.89%
|
25.64
|
| Total Debt |
|
—
|
—
|
—
|
0.00
|
| Capital Lease Obligations |
|
—
|
—
|
—
|
0.00
|
| Net Tangible Assets |
|
12.44
-35.56%
|
19.31
+13.88%
|
16.95
-33.89%
|
25.64
|
| Tangible Book Value |
|
12.44
-35.56%
|
19.31
+13.88%
|
16.95
-33.89%
|
25.64
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-12.89
+4.89%
|
-13.56
-11.32%
|
-12.18
+51.31%
|
-25.01
|
| Cash Flow From Continuing Operating Activities |
|
-12.89
+4.89%
|
-13.56
-11.32%
|
-12.18
+51.31%
|
-25.01
|
| Net Income From Continuing Operations |
|
-12.60
+2.77%
|
-12.96
+9.30%
|
-14.29
+87.32%
|
-112.66
|
| Depreciation Amortization Depletion |
|
0.02
-2.70%
|
0.02
+216.48%
|
0.01
-96.22%
|
0.19
|
| Depreciation |
|
—
|
—
|
0.01
-96.22%
|
0.19
|
| Depreciation And Amortization |
|
0.02
-2.70%
|
0.02
+216.48%
|
0.01
-96.22%
|
0.19
|
| Other Non Cash Items |
|
0.04
+123.97%
|
0.02
|
—
|
72.52
|
| Stock Based Compensation |
|
0.48
-2.31%
|
0.49
+10.12%
|
0.44
-97.38%
|
16.98
|
| Operating Gains Losses |
|
0.10
+232.76%
|
-0.07
-284.45%
|
0.04
+113.83%
|
-0.28
|
| Net Foreign Currency Exchange Gain Loss |
|
0.10
+232.76%
|
-0.07
-284.45%
|
0.04
+113.83%
|
-0.28
|
| Change In Working Capital |
|
-0.93
+11.97%
|
-1.06
-165.20%
|
1.62
+192.05%
|
-1.76
|
| Change In Prepaid Assets |
|
-0.22
-125.40%
|
-0.10
-121.39%
|
0.45
-79.36%
|
2.19
|
| Change In Payables And Accrued Expense |
|
-0.71
-65.49%
|
-0.43
-167.39%
|
0.64
+116.95%
|
-3.76
|
| Change In Accrued Expense |
|
-0.06
+44.19%
|
-0.12
+39.10%
|
-0.19
+93.47%
|
-2.90
|
| Change In Payable |
|
-0.65
-105.82%
|
-0.31
-137.97%
|
0.83
+196.38%
|
-0.86
|
| Change In Account Payable |
|
-0.65
-105.82%
|
-0.31
-137.97%
|
0.83
+196.38%
|
-0.86
|
| Change In Other Working Capital |
|
—
|
-0.53
-200.00%
|
0.53
|
—
|
| Change In Other Current Liabilities |
|
—
|
—
|
0.00
+100.00%
|
-0.19
|
| Investing Cash Flow |
|
0.00
+100.00%
|
-0.02
+83.37%
|
-0.09
|
0.00
|
| Cash Flow From Continuing Investing Activities |
|
0.00
+100.00%
|
-0.02
+83.37%
|
-0.09
|
0.00
|
| Net PPE Purchase And Sale |
|
0.00
+100.00%
|
-0.02
+83.37%
|
-0.09
|
0.00
|
| Purchase Of PPE |
|
0.00
+100.00%
|
-0.02
+83.37%
|
-0.09
|
0.00
|
| Capital Expenditure |
|
—
|
-0.02
+83.37%
|
-0.09
|
—
|
| Financing Cash Flow |
|
4.64
-68.69%
|
14.82
+188.36%
|
5.14
+652.59%
|
0.68
|
| Cash Flow From Continuing Financing Activities |
|
4.64
-68.69%
|
14.82
+188.36%
|
5.14
+652.59%
|
0.68
|
| Net Common Stock Issuance |
|
5.05
-68.73%
|
16.14
+178.81%
|
5.79
+747.61%
|
0.68
|
| Proceeds From Stock Option Exercised |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Other Financing Charges |
|
-0.41
+69.10%
|
-1.32
-103.18%
|
-0.65
|
—
|
| Changes In Cash |
|
-8.25
-760.50%
|
1.25
+117.53%
|
-7.13
+70.69%
|
-24.33
|
| Effect Of Exchange Rate Changes |
|
0.00
+165.16%
|
-0.01
+14.50%
|
-0.01
-121.67%
|
0.04
|
| Beginning Cash Position |
|
22.89
+5.74%
|
21.65
-24.80%
|
28.79
-45.76%
|
53.08
|
| End Cash Position |
|
14.64
-36.04%
|
22.89
+5.74%
|
21.65
-24.80%
|
28.79
|
| Free Cash Flow |
|
-12.89
+4.99%
|
-13.57
-10.61%
|
-12.27
+50.94%
|
-25.01
|
| Common Stock Issuance |
|
5.05
-68.73%
|
16.14
+178.81%
|
5.79
+747.61%
|
0.68
|
| Issuance Of Capital Stock |
|
5.05
-68.73%
|
16.14
+178.81%
|
5.79
+747.61%
|
0.68
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
—
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-04-01 View
- 42026-04-01 View
- 8-K2026-04-01 View
- 8-K2026-03-30 View
- 42026-03-16 View
- 42026-03-16 View
- 10-K2026-03-16 View
- 8-K2026-03-16 View
- 8-K2026-02-18 View
- 42026-02-02 View
- 42026-02-02 View
- 8-K2026-01-29 View
- 8-K2026-01-23 View
- 8-K2026-01-09 View
- 42025-12-11 View
- 42025-12-11 View
- 42025-12-11 View
- 8-K2025-12-09 View
- 10-Q2025-11-12 View
- 8-K2025-11-12 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|